

A P P E N D I X

C

**Commissioners' voting
on recommendations**

Commissioners' voting on recommendations

In the Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000, the Congress required MedPAC to call for individual Commissioner votes on each recommendation, and to document the voting record in its report. The information below satisfies that mandate.

Chapter 1: Geographic variation in per beneficiary Medicare expenditures

No recommendations

Chapter 2: Market variation: implications for beneficiaries and policy reform

No recommendations

Chapter 3: Accounting for variation in hospital financial performance under prospective payment

No recommendations

Chapter 4: Growth and variation in use of physician services

No recommendations

Chapter 5: Monitoring post-acute care

No recommendations

Chapter 6: Quality of dialysis care and providers' costs

No recommendations

Chapter 7: Using incentives to improve the quality of care in Medicare

The Secretary should conduct demonstrations to evaluate provider payment differentials and structures that reward and improve quality.

Yes: DeBusk, DeParle, Durenberger, Feezor, Hackbarth, Muller, Nelson, Newhouse, Raphael, Reischauer, Rosenblatt, Smith, Stowers, Wakefield, Wolter

Absent: Burke, Rowe

Chapter 8: Using market competition in fee-for-service Medicare

8A The Congress should give the Secretary demonstration authority to initiate competitive pricing demonstrations.

Yes: DeBusk, DeParle, Durenberger, Feezor, Hackbarth, Muller, Nelson, Newhouse, Raphael, Reischauer, Smith, Stowers, Wakefield, Wolter

Absent: Burke, Rosenblatt, Rowe

8B For demonstrations that prove successful, the Secretary should have the authority to implement competitive pricing. The Congress should have a fixed period of time to review and approve any implementation plan.

Yes: DeBusk, DeParle, Durenberger, Feezor, Hackbarth, Muller, Nelson, Newhouse, Raphael, Reischauer, Smith, Stowers, Wakefield, Wolter

Absent: Burke, Rosenblatt, Rowe

Chapter 9: Medicare payments for outpatient drugs under Part B

No recommendations